ArticleNature communications2024
Epigenetic reprogramming shapes the cellular landscape of schwannoma.
Open access · goldAbstract read
In one paragraph
Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
9.6field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 26 citations in OpenAlex.
- Whole Body-MRI assessment of peripheral lesions in patients with NF2-related schwannomatosis on systemic bevacizumab.Journal of neuro-oncology · 2025Trial
- Targeting the nervous system: Mechanistic insights into neuro-tumor communication and therapeutic opportunities.Acta pharmaceutica Sinica. B · 2026Review
- Blood immune profiling predicts surgical anatomy and facial nerve outcome in Vestibular Schwannoma.Journal of neuro-oncology · 2026Article
- IL6 Supports Development of an Immunosuppressive Microenvironment and Resistance to Therapy in Glioblastoma.Cancer research · 2026Article
- Combinatorial multiomic analysis from a pedigree of Sox10Dom Hirschsprung mice identifies multiple high confidence candidate modifiers of Enteric Nervous System development.PLoS computational biology · 2026Article
- DNA-PKcs inhibition sensitizes glioblastoma to radiotherapy through reprogramming of tumor cell states and immune microenvironment cell types.Research square · 2026Article
- Beyond chromatin accessibility: bulk ATAC-seq as an integrative assay to portray genomes and epigenomes.NAR genomics and bioinformatics · 2026Article
- Quantitative imaging of schwannoma captures heterogeneity and accelerates preclinical testing, revealing distinct impacts of targeted therapies.bioRxiv : the preprint server for biology · 2026Article
- IFN signaling is associated with radiotherapy response in malignant peripheral nerve sheath tumors.The Journal of clinical investigation · 2026Article
- Special Issue: The Evolving Landscape of Single-Cell Genomics in CNS and PNS Oncology.Neuro-oncology advances · 2026Review
- Single-cell multi-omic techniques highlight the diverse composition and intercellular interactions of the vestibular schwannoma tumor microenvironment.Neuro-oncology advances · 2026Article
- Schwannomatosis tumor modeling: progress and prospects for translational research.Journal of biological engineering · 2026Review
- Inhibition of focal adhesion kinase impairs tumor formation and preserves hearing in a murine model of NF2-related schwannomatosis.Science advances · 2026Article
- Molecular and genetic insights into vestibular schwannoma.Journal of neuro-oncology · 2026Review
- Combined single-cell transcriptome and Mendelian randomization to identify and validate prognostic genes associated with endoplasmic reticulum stress and butyrate metabolism in lung adenocarcinoma.Frontiers in genetics · 2026Article
- Combinatorial multiomic analysis from a pedigree of Sox10bioRxiv : the preprint server for biology · 2025Article
- The clinical value and application of augmented reality navigation in brachial plexus schwannoma.Scientific reports · 2025Article
- Genetic and clinical characteristics of cranial nerve schwannoma harboring SH3PXD2A-HTRA1 fusion gene.Acta neuropathologica · 2025Article
- Multiplexed epigenetic memory editing using CRISPRoff sensitizes glioblastoma to chemotherapy.Neuro-oncology · 2025Article
- Multiplatform molecular analyses reveal two molecular subgroups of NF2-related schwannomatosis vestibular schwannomas with distinct tumour microenvironment and therapeutic vulnerabilities.Acta neuropathologica · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
34 authors at 5 institutions in 1 country.
S John LiuDepartment of Radiation Oncology, University of California San Francisco, San Francisco, CA, 94143, USA.ORCID 0000-0003-1042-0191
Tim Casey-Clyde *Department of Radiation Oncology, University of California San Francisco, San Francisco, CA, 94143, USA.ORCID 0000-0002-9281-4073
Nam Woo Cho *Department of Radiation Oncology, University of California San Francisco, San Francisco, CA, 94143, USA.
Jason SwindermanArc Institute, Palo Alto, CA, 94304, USA.
Melike PekmezciDepartment of Pathology, University of California San Francisco, San Francisco, CA, 94143, USA.ORCID 0000-0003-2548-8359
Mark C DoughertyDepartments of Otolaryngology and Neurosurgery, University of Iowa, Iowa City, IA, 52242, USA.ORCID 0000-0003-3247-0261
Kyla FosterDepartment of Radiation Oncology, University of California San Francisco, San Francisco, CA, 94143, USA.ORCID 0000-0002-8452-6397
William C ChenDepartment of Radiation Oncology, University of California San Francisco, San Francisco, CA, 94143, USA.
Javier E Villanueva-MeyerDepartment of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA, USA.
Danielle L SwaneyJ. David Gladstone Institutes, California Institute for Quantitative Biosciences, Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, 94158, USA.ORCID 0000-0001-6119-6084
Harish N VasudevanDepartment of Radiation Oncology, University of California San Francisco, San Francisco, CA, 94143, USA.
Abrar ChoudhuryDepartment of Radiation Oncology, University of California San Francisco, San Francisco, CA, 94143, USA.ORCID 0000-0001-8312-2457
Joanna PakDepartment of Radiation Oncology, University of California San Francisco, San Francisco, CA, 94143, USA.
Jonathan D BreshearsDepartment of Neurological Surgery, University of California San Francisco, San Francisco, CA, 94143, USA.
Ursula E LangDepartment of Pathology, University of California San Francisco, San Francisco, CA, 94143, USA.
Charlotte D EatonDepartment of Radiation Oncology, University of California San Francisco, San Francisco, CA, 94143, USA.
Kamir J Hiam-GalvezParker Institute for Cancer Immunotherapy, Chan Zuckerberg Biohub, and Departments of Otolaryngology, and Microbiology and Immunology, University of California San Francisco, San Francisco, CA, 94115, USA.
Erica StevensonJ. David Gladstone Institutes, California Institute for Quantitative Biosciences, Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, 94158, USA.
Kuei-Ho ChenJ. David Gladstone Institutes, California Institute for Quantitative Biosciences, Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, 94158, USA.
Brian V LienDepartment of Neurological Surgery, University of California San Francisco, San Francisco, CA, 94143, USA.
David WuDepartment of Neurological Surgery, University of California San Francisco, San Francisco, CA, 94143, USA.
Steve E BraunsteinDepartment of Radiation Oncology, University of California San Francisco, San Francisco, CA, 94143, USA.
Penny K SneedDepartment of Radiation Oncology, University of California San Francisco, San Francisco, CA, 94143, USA.
Stephen T MagillDepartment of Neurological Surgery, Northwestern University, Chicago, IL, 60611, USA.
Daniel LimDepartment of Neurological Surgery, University of California San Francisco, San Francisco, CA, 94143, USA.
Michael W McDermottBaptist Health Miami Neuroscience Institute, Miami, FL, 33176, USA.
Mitchel S BergerDepartment of Neurological Surgery, University of California San Francisco, San Francisco, CA, 94143, USA.
Arie PerryDepartment of Neurological Surgery, University of California San Francisco, San Francisco, CA, 94143, USA.ORCID 0000-0002-8300-7261
Nevan J KroganJ. David Gladstone Institutes, California Institute for Quantitative Biosciences, Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, 94158, USA.ORCID 0000-0003-4902-337X
Marlan R HansenDepartments of Otolaryngology and Neurosurgery, University of Iowa, Iowa City, IA, 52242, USA.
Matthew H SpitzerParker Institute for Cancer Immunotherapy, Chan Zuckerberg Biohub, and Departments of Otolaryngology, and Microbiology and Immunology, University of California San Francisco, San Francisco, CA, 94115, USA.ORCID 0000-0002-5291-3819
Luke GilbertArc Institute, Palo Alto, CA, 94304, USA.ORCID 0000-0001-5854-0825
Philip V TheodosopoulosDepartment of Neurological Surgery, University of California San Francisco, San Francisco, CA, 94143, USA.
David R RaleighDepartment of Radiation Oncology, University of California San Francisco, San Francisco, CA, 94143, USA. david.raleigh@ucsf.edu.ORCID 0000-0001-9299-8864
University of California, San Francisco · USQB3 · USUniversity of Iowa · USBaptist Health South Florida · USNorthwestern University · US
Funding
MOLECULAR AND CELLULAR IMMUNOLOGYT32AI007334 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CYSTER, JASON G · 1988 to 2023
$11.0MUsing Networks to Seed Hierarchical Whole-cell Models of CancerU54CA209891 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KROGAN, NEVAN J · 2017 to 2021
$10.9MTraining Program in Translational Brain Tumor ResearchT32CA151022 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Joseph F Costello · 2010 to 2026
$6.6MMechanisms of Hedgehog signaling in glioblastomaR01CA251221 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI RALEIGH, DAVID R · 2021 to 2025
$2.6MUCSF Paul Calabresi K12 Career Development Program in Clinical OncologyK12CA260225 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BERGSLAND, EMILY K, BIVONA, TREVER G · 2021 to 2025
$2.6MIllumina NovaSeq 6000 Sequencing SystemS10OD028511 · OD · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CHOW, ERIC D · 2020 to 2020
$583kBiochemical mechanisms of Hedgehog signal transduction through primary ciliaR21HD106238 · NICHD · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI RALEIGH, DAVID R · 2022 to 2023
$444kNCI NIH HHS K12 CA260225NCI NIH HHS R01 CA251221NCI NIH HHS T32 CA151022NCI NIH HHS U54 CA209891NIAID NIH HHS T32 AI007334NICHD NIH HHS R21 HD106238NIH HHS S10 OD028511
Abstract
Mechanisms specifying cancer cell states and response to therapy are incompletely understood. Here we show epigenetic reprogramming shapes the cellular landscape of schwannomas, the most common tumors of the peripheral nervous system. We find schwannomas are comprised of 2 molecular groups that are distinguished by activation of neural crest or nerve injury pathways that specify tumor cell states and the architecture of the tumor immune microenvironment. Moreover, we find radiotherapy is sufficient for interconversion of neural crest schwannomas to immune-enriched schwannomas through epigenetic and metabolic reprogramming. To define mechanisms underlying schwannoma groups, we develop a technique for simultaneous interrogation of chromatin accessibility and gene expression coupled with genetic and therapeutic perturbations in single-nuclei. Our results elucidate a framework for understanding epigenetic drivers of tumor evolution and establish a paradigm of epigenetic and metabolic reprograming of cancer cells that shapes the immune microenvironment in response to radiotherapy.
Indexed as
NeurilemmomaCellular ReprogrammingEpigenesis, GeneticHumansTumor Microenvironment
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.